pairingsPairing
AI pathology → androgen deprivation duration
An AI reading of the biopsy slide says whether adding hormone therapy to radiation will help.
ArteraAI Prostate (FDA de novo 2025) predicts benefit from short-term ADT in intermediate-risk prostate cancer using RTOG trial slides; NCCN-listed.
Rationale
Morphology encodes biology beyond Gleason grade; trained on randomised trial cohorts so the prediction is causal for treatment effect.
Evidence
Validated on phase 3 cohorts; FDA-authorised.
Pages like this
not linked directly; found by shared links- CompanyArtera
Shares ArteraAI Prostate, Digital pathology & AI, Prostate cancer.
- PersonAmar U. Kishan
Shares ArteraAI Prostate, Prostate cancer.
- IdeaUse food effects to cut the dose and cost of oral drugs that absorb better with meals
Shares Androgen deprivation & AR pathway inhibitors, Prostate cancer.
- ProductDecipher Prostate
Shares ArteraAI Prostate, Prostate cancer.
- TermGleason score / Grade Group
Shares Digital pathology & AI, Prostate cancer.
- IdeaCardiometabolic screening and treatment for survivors on long-term hormone therapy
Shares Androgen deprivation & AR pathway inhibitors, Prostate cancer.
- ProductRelugolix
Shares Androgen deprivation & AR pathway inhibitors, Prostate cancer.
- ProductBicalutamide
Shares Androgen deprivation & AR pathway inhibitors, Prostate cancer.